Mind Medicine (MindMed) Inc
NASDAQ:MNMD

Watchlist Manager
Mind Medicine (MindMed) Inc Logo
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
Watchlist
Price: 7.32 USD 3.39%
Market Cap: 536.8m USD
Have any thoughts about
Mind Medicine (MindMed) Inc?
Write Note

Mind Medicine (MindMed) Inc
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Mind Medicine (MindMed) Inc
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
Additional Paid In Capital
$625.5m
CAGR 3-Years
214%
CAGR 5-Years
279%
CAGR 10-Years
N/A
Bausch Health Companies Inc
TSX:BHC
Additional Paid In Capital
$201m
CAGR 3-Years
-23%
CAGR 5-Years
-13%
CAGR 10-Years
-2%
Canopy Growth Corp
TSX:WEED
Additional Paid In Capital
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Sundial Growers Inc
NASDAQ:SNDL
Additional Paid In Capital
CA$73m
CAGR 3-Years
7%
CAGR 5-Years
50%
CAGR 10-Years
N/A
Cronos Group Inc
TSX:CRON
Additional Paid In Capital
$51.5m
CAGR 3-Years
19%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
C
Curaleaf Holdings Inc
CNSX:CURA
Additional Paid In Capital
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Mind Medicine (MindMed) Inc
Glance View

Market Cap
536.8m USD
Industry
Pharmaceuticals

Mind Medicine (MindMed), Inc. operates as a neuro-pharmaceutical company that discovers, develops and deploys psychedelic medicines to improve health, promote wellness and alleviate suffering. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2015-05-04. The firm focuses on discovering, developing and deploying psychedelic-inspired medicines and therapies to address addiction and mental illness. The firm's commercial drug development programs includes lysergic acid diethylamide (LSD) experiential therapy, 18-methoxycoronaridine (18-MC) opioid withdrawal, LSD microdosing, methylenedioxymethamphetamine (MDMA), and dimethyltryptamine (DMT). The firm's subsidiaries include Mind Medicine, Inc., HealthMode, Inc., MindMed Pty Ltd. and MindMed GmbH.

MNMD Intrinsic Value
2.22 USD
Overvaluation 70%
Intrinsic Value
Price

See Also

What is Mind Medicine (MindMed) Inc's Additional Paid In Capital?
Additional Paid In Capital
625.5m USD

Based on the financial report for Sep 30, 2024, Mind Medicine (MindMed) Inc's Additional Paid In Capital amounts to 625.5m USD.

What is Mind Medicine (MindMed) Inc's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 5Y
279%

Over the last year, the Additional Paid In Capital growth was 73%. The average annual Additional Paid In Capital growth rates for Mind Medicine (MindMed) Inc have been 214% over the past three years , 279% over the past five years .

Back to Top